Indoraggu Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 159.52%
- Profit Growth 190.91%
- Ebitda 751.53%
- Net Worth 69.00%
- Total Assets 104.51%
About Indoraggu Pharmaceuticals
Indoraggu Pharmaceuticals Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 September 2019 (Five years and four months 6 days old ). Its registered office is in Mysore, Karnataka, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Mahadeva Doddachari and Basavaraju Prabhuswamy serve as directors at the Company.
Company Details
-
Location
Mysore, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KA2019PTC128366
-
Company No.
128366
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Sep 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Indoraggu Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahadeva Doddachari
|
Director | 28-Sep-2019 | Current |
|
Basavaraju Prabhuswamy
|
Director | 28-Sep-2019 | Current |
Financial Performance of Indoraggu Pharmaceuticals.
Indoraggu Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 159.52% increase. The company also saw a substantial improvement in profitability, with a 190.91% increase in profit. The company's net worth Soared by an impressive increase of 69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indoraggu Pharmaceuticals?
Unlock access to Indoraggu Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indoraggu Pharmaceuticals?
Unlock and access historical data on people associated with Indoraggu Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indoraggu Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indoraggu Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
